Biotech News News 20 December 2025

Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

New York time check: It is Friday, December 26, 2025, 12:17 p.m. ET in New York. While the broader U.S. market is mostly drifting near record territory in subdued post‑holiday volume, Regencell Bioscience Holdings Limited (Nasdaq: RGC) is doing what

26 December 2025

Biotech News·Stock Market

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is

26 December 2025

Biotech News·Financial Analysis·Investment Strategies·Pharmaceutical Industry·Stock Market

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation (NASDAQ: OMER) is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to

24 December 2025

Biotech News·FDA Approvals·Investing·Pharmaceutical Industry·Stock Market

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI

24 December 2025

Biotech News·FDA Updates·Financial Trends·Investment Analysis·Stock Market

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy (HCM). By late morning, shares were trading around $26.37—up roughly

24 December 2025

Analyst Forecasts·Biotech News·Investment Strategies·Pharmaceutical Industry·Stock Market

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (Nasdaq: RZLT) is still in the spotlight on December 24, 2025, after a brutal mid-December selloff tied to its pivotal clinical trial news—and a wave of follow-on analyst downgrades, price-target resets, and investor-law-firm investigations. As of the latest

24 December 2025

Biotech News·Company Analysis·Financial Forecasts·Investment Insights·Stock Market

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is back in the rare-disease spotlight on December 22, 2025, as investors digest a blockbuster acquisition, a quiet pipeline pruning, and a new round of analyst price-target resets. As of 20:24 UTC (3:24 p.m. ET),

22 December 2025

Biotech News·Investment Analysis·Stock Market

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

December 22, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight as its stock price whipsaws following a sharp late-week surge and a fresh round of market commentary that mixes optimism about the company’s muscle-disease pipeline with

22 December 2025

Biotech News·Financial Forecasts·Investment Analysis·Market Trends·Stock Market

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics, Incorporated (NASDAQ: CYTK) surged on Monday, December 22, 2025, extending a sharp rally that followed the company’s first-ever U.S. drug approval. Shares traded around $69.68 in the session, up roughly 11% from the prior close, after reaching an intraday

22 December 2025

Analyst Ratings·Biotech News·FDA Approvals·Investment Insights·Stock Market

Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) stock is no longer trading like a typical biotech momentum name—at least not this week. As of December 22, 2025, the stock is hovering around $14.18, tightly anchored to the $14.50 per-share all-cash buyout BioMarin

22 December 2025

Analyst Insights·Biotech News·Investment Updates·Mergers & Acquisitions·Stock Market

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

December 20, 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the year’s final stretch with investors focused on a familiar question: can the biotech’s next wave of launches and late-stage programs begin to meaningfully diversify a cystic fibrosis (CF)

21 December 2025

Analyst Forecasts·Biotech News·Investment Insights·Pharmaceutical Industry·Stock Market

Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching

Biogen Inc. stock (NASDAQ: BIIB) is ending the week on a stronger note after a sharp, high-volume move on Friday’s session—an attention-grabbing setup heading into late December when liquidity often thins and headlines can move shares quickly. As of Saturday,

20 December 2025

Biotech News·Earnings Reports·Investment Tips·Stock Analysis·Stock Market

Biotech News News 20 December 2025 - 26 December 2025